Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection.
Despite a decade of human immunodeficiency virus (HIV) seropositivity, a few individuals termed as long-term nonprogressors (LTNPs) maintain a stable CD4+ T-cell count for a period of time. The aim of this study was to establish, through the sequential determination of all known predictors of HIV disease, the proportion of such patients having stringent criteria of true long-term nonprogression. Among 249 individuals who were HIV-infected and prospectively followed up over a 10-year period (1985 to 1995), 12 having a CD4+ T-cell count greater than 500/microL (LTNP I group) and 9 having a CD4+ T-cell count less than 500 but stable over time (LTNP II group) after at least 10 years of infection without intervention of antiviral therapy, were studied over the entire follow-up period. The plasma HIV RNA copy number and the serum concentrations of p24 antigen, each anti-HIV antibody, neopterin, beta-2-microglobulin, Immunoglobulin (Ig) G and IgA were determined every 18 months over the study period. Cellular and plasma viremias were cross-sectionaly assayed in all 21 patients. Only two patients had strictly no marker of progression over the follow-up period. They were the only ones who had, over the 10-year period, a viral copy number too low to be detected. The other patients had a viral copy number higher than 400/mL at at least one visit and increasing over the follow-up period, and they evidenced one or more markers of virological or immunological deterioration. Cellular viremia was positive in all patients but two, while plasma viremia was negative in all but one. The population of individuals termed as LTNPs is not virologically and immunologically homogeneous. The majority present biological signs of HIV disease progression. A new pattern of true LTNP can be drawn through stringent criteria based on the whole known predictors. This pattern appears to be rare in HIV-positive population.
Lefrère
J J
JJ
Institut National de la Transfusion Sanguine, Paris, France.
Morand-Joubert
L
L
Mariotti
M
M
Bludau
H
H
Burghoffer
B
B
Petit
J C
JC
Roudot-Thoraval
F
F
D000328:Adult; D001708:Biopterins / Q000031:analogs & derivatives / Q000032:analysis; D018791:CD4 Lymphocyte Count; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015483:HIV Antibodies / Q000097:blood; D016655:HIV Core Protein p24 / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000276:immunology / Q000473:pathology*; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007962:Leukocytes / Q000821:virology; D008297:Male; D008875:Middle Aged; D019798:Neopterin; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D017741:Survivors; D013997:Time Factors; D014766:Viremia / Q000276:immunology / Q000473:pathology; D001613:beta 2-Microglobulin / Q000032:analysis
D015483:HIV Antibodies; D016655:HIV Core Protein p24; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D012367:RNA, Viral; D001613:beta 2-Microglobulin; D001708:Biopterins; D019798:Neopterin